Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Teva announced the launch of QNASL (beclomethasone dipropionate) Nasal Aerosol in a new 40mcg strength. QNASL Nasal Aerosol 40mcg is indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in patients aged ≥4 years.
QNASL Nasal Aerosol is an intranasal corticosteroid that is extensively converted to the active metabolite, beclomethasone-17-monopropionate. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (eg, mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and the release of inflammatory mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines).
RELATED: First Waterless Nasal Spray Approved for Children
The new QNASL Nasal Aerosol 40mcg has a built-in dose counter and is available in a 4.9g package containing 60 actuations. QNASL is already available in a 80mcg strength for use in patients aged ≥12 years.
For more information call (855) 55-QNASL or visit QNASL.com.
